TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily
Brief Summary: Comparison of two asthma treatments by lung function measures.


Options:
A: Arm Label: CHF 5993 200/6/12.5 µg; Type: EXPERIMENTAL; Interventions: Drug: CHF 5993 200/6/12.5 µg | Arm Label: CHF 1535 200/6 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHF 1535 200/6 µg | Arm Label: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg | Intervention Type: DRUG; Name: CHF 5993 200/6/12.5 µg; Assigned to Arm(s): CHF 5993 200/6/12.5 µg | Intervention Type: DRUG; Name: CHF 1535 200/6 µg; Assigned to Arm(s): CHF 1535 200/6 µg | Intervention Type: DRUG; Name: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg; Assigned to Arm(s): CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Symbicort pMDI + budesonide HFA pMDI | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Symbicort pMDI + budesonide HFA pMDI; Assigned to Arm(s): 2
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1
D: Arm Label: Fluticasone/ Formoterol (Flutiform); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone/ Formoterol | Arm Label: Fluticasone/ salmeterol (Seretide); Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/ salmeterol | Intervention Type: DRUG; Name: Fluticasone/ Formoterol; Assigned to Arm(s): Fluticasone/ Formoterol (Flutiform) | Intervention Type: DRUG; Name: fluticasone/ salmeterol; Assigned to Arm(s): Fluticasone/ salmeterol (Seretide)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily
Brief Summary: Comparison of two asthma treatments by lung function measures.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to tiotropium | Arm Label: Tiotropium 18 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg, Drug: Placebo to indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 µg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Tiotropium 18 µg | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): Indacaterol 150 µg
C: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149, Drug: Salbutamol/albuterol | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237, Drug: Salbutamol/albuterol | Arm Label: open-label tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium, Drug: Salbutamol/albuterol | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): open-label tiotropium | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): NVA237, QVA149, open-label tiotropium
D: Intervention Type: DRUG; Name: SPIRIVA; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily
Brief Summary: Comparison of two asthma treatments by lung function measures.


Options:
A: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1
C: Intervention Type: DRUG; Name: budesonide/formoterol, 2x 200/6 microgram. 4 times daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisolone, 30 mg once daily and placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to assess the effectiveness of pregabalin, duloxetine and amitriptyline compared with placebo in reducing pain in diabetic patients as assessed by Brief Pain Inventory (BPI).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
C: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Milnacipran, Placebo
D: Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 50mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 100mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 200mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 400mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): desvenlafaxine succinate sustained-release (DVS SR) 100mg, desvenlafaxine succinate sustained-release (DVS SR) 200mg, desvenlafaxine succinate sustained-release (DVS SR) 400mg, desvenlafaxine succinate sustained-release (DVS SR) 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to assess the effectiveness of pregabalin, duloxetine and amitriptyline compared with placebo in reducing pain in diabetic patients as assessed by Brief Pain Inventory (BPI).


Options:
A: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + CBT-I | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT-I plus placebo antidepressant medication | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram + CBT-I; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: CBT-I plus placebo antidepressant medication; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to assess the effectiveness of pregabalin, duloxetine and amitriptyline compared with placebo in reducing pain in diabetic patients as assessed by Brief Pain Inventory (BPI).


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine
C: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to assess the effectiveness of pregabalin, duloxetine and amitriptyline compared with placebo in reducing pain in diabetic patients as assessed by Brief Pain Inventory (BPI).


Options:
A: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
B: Arm Label: Imipramine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipramine | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Imipramine plus pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Imipramine, pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Imipramine; Assigned to Arm(s): Imipramine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Imipramine, pregabalin; Assigned to Arm(s): Imipramine plus pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1: Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)


Options:
A: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
B: Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A
C: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.3 mg intravitreal ranibizumab | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: 2.0 mg intravitreal aflibercept | Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: 1.25 mg intravitreal bevacizumab | Intervention Type: DRUG; Name: 2.0 mg intravitreal aflibercept; Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: 1.25 mg intravitreal bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: 0.3 mg intravitreal ranibizumab; Assigned to Arm(s): Ranibizumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)


Options:
A: Arm Label: Sham + intravitreal ranibizumab 0.3 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravitreal ranibizumab 0.3 mg, Procedure: Sham injection | Arm Label: Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg; Type: EXPERIMENTAL; Interventions: Drug: intravitreal ranibizumab 0.3 mg, Drug: dexamethasone intravitreal implant | Intervention Type: DRUG; Name: intravitreal ranibizumab 0.3 mg; Assigned to Arm(s): Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg, Sham + intravitreal ranibizumab 0.3 mg | Intervention Type: DRUG; Name: dexamethasone intravitreal implant; Assigned to Arm(s): Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg | Intervention Type: PROCEDURE; Name: Sham injection; Assigned to Arm(s): Sham + intravitreal ranibizumab 0.3 mg
B: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A
C: Arm Label: AVASTIN; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: OZURDEX; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): AVASTIN | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): OZURDEX
D: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
C: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
D: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial
Brief Summary: In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Avastin (Bevacizumab) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Avastin (Bevacizumab) | Intervention Type: DRUG; Name: Avastin (Bevacizumab); Assigned to Arm(s): 1, 2
B: Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of bevacizumab | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal injection of ranibizumab (0.5 mg per dose) | Intervention Type: DRUG; Name: Intravitreal injection of bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Intravitreal injection of ranibizumab (0.5 mg per dose); Assigned to Arm(s): Ranibizumab
C: Arm Label: 1-ranibizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: 2-ranibizumab with laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: 3-laser monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 1-ranibizumab monotherapy, 2-ranibizumab with laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): 2-ranibizumab with laser, 3-laser monotherapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 2, 3 | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recombinant Human Activated Factor VII as Salvage Therapy in Women With Severe Postpartum Hemorrhage
Brief Summary: The aim of this clinical research project is to evaluate the use of the recombinant human activated factor VII (rhFVIIa), given as a salvage therapy, in women with a dramatic postpartum hemorrhage still ongoing after all the currently available medical and surgical treatments. We are going to compare its early use, before elective surgery or arterial embolization, to its late use, after embolization or surgery, before salvage hysterectomy.


Options:
A: Arm Label: Standard care for post-partum hemorrhage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Arm Label: rFVIIa; Type: EXPERIMENTAL; Interventions: Drug: rFVIIa | Intervention Type: DRUG; Name: rFVIIa; Assigned to Arm(s): rFVIIa | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard care for post-partum hemorrhage
B: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
C: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2

Answer: A